Interim results for the 6 months to 30 June 2015

Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Interim results for the six months to 30 June 2015

Oxford Pharmascience Group Plc is pleased to announce its unaudited interim results for the six months to 30 June 2015.

HIGHLIGHTS

• Progression to clinic with two OXPzero™ NSAIDS for assessment of both pharmacokinetics and reduction in gastric irritation via endoscopy :

- OXP005 (250mg OXPzero™ Naproxen tablet)

- OXP001(2) (400mg Chewable OXPzero™ Ibuprofen tablet)

• OXPzero™ Naproxen /OXP005:

- Encouraging proof of concept trial results announced July 2015 demonstrating:

- major statistically significant reduction in gastric erosions

- comparable PK profile to the reference Naprosyn

- Programme initiated to further improve OXP005 to also meet reduction in Lanza score endpoint.

• OXPzero™ Ibuprofen - OXP001(2):

- Taste masking benefit demonstrated in clinical setting

- Successfully met optimisation objectives for immediate release and complete drug absorption (announced in August 2015)

- Proof-of-concept trial ongoing with headline results on the endoscopy phase expected to be released in Q4 2015, including further PK data

• £20 million gross proceeds raised from a placing of new ordinary shares completed in June 2015, to enable the Company to pursue a wider range of opportunities across its portfolio and provide both flexibility and balance sheet strength as the Company progresses into the commercialisation phase.

• Total cash, cash equivalents and deposits of £24.1m at 30 June 2015 (2014: £8.2m).

Marcelo Bravo, Chief Executive Officer, commented:

"The Company has initiated contact with major pharmaceutical companies in the NSAID space. With additional endoscopy data from its further pilot clinical study for OXP001(2) expected by Q4 2015, the plan remains to progress to partnering discussions with the aim of maximising value for the Company and its shareholders.

In addition, the Company will be allocating resources to investigate and pursue a wider range of opportunities leading with the development of OXPzero™ Aspirin and also the evaluation of further applications of its technologies.

Building upon the progress made this year, the Company is in a strong position to proceed along its clinical pathway and to diversify its pipeline. We look forward to announcing further updates on the Company's programmes and pipeline over the coming year."

For further information:

Oxford Pharmascience Group Plc

Marcelo Bravo, Chief Executive +44 20 7554 5875

N+1 Singer

Aubrey Powell / Jen Boorer +44 20 7496 3000

OVERVIEW

The Company has made significant progress in 2015, with a clear focus on its NSAID programme. Having progressed from the lab to the clinic with two of the most important molecules in the multi-billion dollar NSAIDs category, namely ibuprofen and naproxen, we enter the second half of 2015 in a strong position, with the technology moving ahead, a more robust clinical data set in place, and a strong balance sheet.

We are very pleased that the data available to date demonstrates that the technology is providing a class effect, significantly reducing gastric erosions not only with ibuprofen but also with the much more gastrointestinally aggressive naproxen molecule. In early January, the Company announced that it had completed successful development of clinical formulations of both OXPzero™ Ibuprofen (OXP001(2)) and OXPzero™ Naproxen (OXP005) that demonstrated immediate and complete drug release in vitro. Both formulations proceeded to proof-of-concept trials in the subsequent months with the objective of demonstrating reduced gastric irritation as well as immediate and complete drug absorption. The two studies conducted have both shown a major, statistically significant reduction in median erosions (60% for ibuprofen in last year's study with an early un-optimised formulation and 38% for naproxen in the OXP005 study recently reported). Importantly, this year's studies have also shown that the formulations are achieving immediate release and complete drug absorption in vivo. Market research previously commissioned by the Company amongst clinicians and payors indicates a highly robust business case for the OXPzero™ technology which could deliver significant returns for shareholders.

The results to date for OXP005 are encouraging with results showing a comparable PK profile to the reference Naprosyn. Building upon this, the Company has initiated a programme to further improve OXP005 to also meet reduction in Lanza score endpoint.

The Company is confident that additional endoscopy data from the further pilot clinical study with OXP001(2) (now in the clinic) will provide for a robust data package with which it will be able to progress to partnering discussions later in 2015. Confirmation of reduction in gastrointestinal erosions for OXP001(2) within the range already established in our first two pilot trials will validate OXPzero™ Ibuprofen as a disruptive compound in the $4bn ibuprofen market.

Solid foundation for further progress

In readiness to move these assets forward to the commercial stage, the Company has advanced the manufacturing process and formulation development whilst strengthening its intellectual property.

Having successfully raised £20m gross proceeds in June 2015, the Company is in a very strong position and whilst building robust data packages for OXP001(2) and OXP005 it is also now able to diversify its pipeline. The Company believes there is significant opportunity in cardiovascular disease (CVD) applications of the OXPzero™ platform and is now in early formulation stage of an OXPzero™ Aspirin product aimed at long-term anti-platelet treatment for CVD. Additionally, the Company is exploring the potential of further applications of both the OXPzero™ and OXPtarget™ platform technologies with a view to selecting one to three candidates to add into the pipeline. This review will not only include applications already in development such as OXPzero™ Diclofenac and Safestat™, but also a number of further targets that have been identified in the past few months.

FINANCIAL RESULTS

Revenue for the six months to 30 June 2015 was £342k (2014: £336k), the majority derived from our partnership with Ache Laboratorios in Brazil. Revenue performance for the half year is consistent with delivery of market expectations for the full year.

The loss before tax was £2.2m (2014: loss of £1.7m) reflecting the higher level of clinical activity compared to the prior period. As described above, the Company has run two proof-of-concept clinical studies in the period, compared to one in the comparative period, resulting in Research and Development spending increasing to £1.5m from £1.0m in the first half of 2014.

Cash, cash equivalents and money held on deposits at the half year-end was £24.1m (2014: £8.2m). At the period end, a total of £15.0m (2014: £nil) has been placed on deposit across different banks, all with strong credit ratings. The maturity profiles of these deposits range from nine to 12 months.

The Company raised gross proceeds of £20.0m from a placing of new ordinary shares at a price of 10 pence per share in June 2015 to certain existing and new institutional shareholders. Issue costs associated with the placing were £0.56m. The additional funds enable the Company to proceed along its clinical pathway with confidence and also allows the expansion of the pipeline. Cash management and tight cost control continue to be a priority for the business and the additional funds raised will not change this mentality.

OUTLOOK

The Company has initiated contact with major pharmaceutical companies in the NSAID space. With additional endoscopy data from its further pilot clinical study for OXP001(2) expected by Q4 2015, the plan remains to progress to partnering discussions with the aim of maximising value for the Company and its shareholders.

In addition, the Company will be allocating resources to investigate and pursue a wider range of opportunities leading with the development of OXPzero™ Aspirin and also the evaluation of further applications of its technologies.

Building upon the progress made this year, the Company is in a strong position to proceed along its clinical pathway and to diversify its pipeline. We look forward to announcing further updates on the Company's programmes and pipeline over the coming year.

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

The loss for the year arises from the Group's continuing operations.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

Approved by the Board and authorised for issue on 21 September 2015.

Marcelo Bravo Chris Hill

Chief Executive Officer Chief Financial Officer

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

NOTES TO THE CONDENSED FINANCIAL STATEMENTS

1) BASIS OF PREPARATION

The interim financial statements of Oxford Pharmascience Group Plc are unaudited condensed consolidated financial statements for the six months to 30 June 2015. These include unaudited comparatives for the six months to 30 June 2014 together with audited comparatives for the year to 31 December 2014.

The Company was incorporated on 7 October 2009 as Oxford Nutrascience Group Plc and changed its name to Oxford Pharmascience Group Plc on 19 May 2011. The Company was specifically created to implement a re-organisation in relation to Oxford Pharmascience Limited (formerly Oxford Nutrascience Limited) which would permit admission of the Group to the AIM market. Under the re-organisation, Oxford Pharmascience Limited became a wholly owned subsidiary of Oxford Pharmascience Group Plc on 27 January 2010.

Shareholders in the company at the time of the re-organisation received shares in Oxford Pharmascience Group Plc in the same proportionate interest as they had in Oxford Pharmascience Limited. The business, operations, assets and liabilities of the Oxford Pharmascience Group under the new holding company immediately after the re-organisation were no different from those immediately before the re-organisation and the Directors have therefore treated this combination as a simple re-organisation using the pooling of interests method of accounting.

The condensed consolidated financial statements do not constitute statutory accounts. The statutory accounts for the year to 31 December 2014 have been reported on by the auditors to Oxford Pharmascience Group Plc and have been filed with the Registrar of Companies. The report of the auditors was unqualified and did not contain a statement under section 498 of the Companies Act 2006.

2) SIGNIFICANT ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared under the historical cost convention in accordance with International Financial Reporting Standards as adopted by the European Union.

The accounting policies adopted are consistent with those followed in the preparation of the annual financial statements of Oxford Pharmascience Group Plc for the year ended 31 December 2014.

3) SEGMENTAL REPORTING

Primary reporting format - business segments 

At 30 June 2015, the Group operated in one business segment, that of the development and commercialisation of medicines via reformulation using advanced pharmaceutic technologies to add value to generic and soon to be generic drugs. All revenues have been generated from continuing operations and are from external customers.

Secondary reporting format - geographical segments

The Group operates in four main geographic areas, although all are managed in the UK. The Group's revenue per geographical segment is as follows:

All the Group's assets are held in the UK and all of its capital expenditure arises in the UK.

4) TAXATION

The Group has accumulated losses available to carry forward against future trading profits. No deferred tax asset has been recognised in respect of tax losses since it is uncertain at the balance sheet date as to whether future profits will be available against which the unused tax losses can be utilised.

5) LOSS PER SHARE (BASIC AND DILUTED)

Basic loss per share is calculated by dividing the loss attributable to equity holders of the parent by the weighted average number of ordinary shares in issue during the period. Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares in issue during the period to assume conversion of all dilutive potential ordinary shares.

The Company has issued employee options over 89,200,000 ordinary shares which are potentially dilutive. There is however, no dilutive effect of these issued options as there is a loss for each of the periods concerned

6) SHARE CAPITAL

As permitted by the provisions of the Companies Act 2006, the Company does not have an upper limit to its authorised share capital.

The acquisition of Oxford Pharmascience Limited in 2010 has been accounted for as a re-organisation using the pooling of interests method of accounting as set out in note 1 to these financial statements and under which the shares issued by the Company are recorded at nominal value together with an amount established as Merger reserve in order to replicate the total issued capital of Oxford Pharmascience Limited as at the acquisition date. 

7) RELATED PARTY TRANSACTIONS

There are no sales or purchases to/from related parties.

During the six month period ended 30 June 2015, the Company entered into numerous transactions with its subsidiary company which net off on consolidation - these have not been shown.

In addition, during the period the Company paid remuneration to the Directors' in accordance with their service contracts and letters of appointment.

8) INTERIM FINANCIAL REPORT

A copy of this interim report will be available on the Company's website at www.oxfordpharmascience.com